Neuronal pentraxin receptor (NPR) is a synaptic protein implicated in AMPA receptor trafficking at excitatory synapses. Since glutamate neurotransmission is disrupted in Alzheimer's disease (AD), NPR levels measured from plasma represent a potential biomarker for synaptic dysfunction associated with AD. We sought to determine the relationship between AD pathology and brain and plasma NPR levels by examining age-associated NPR levels in these compartments in a transgenic APP/PS1 rat model of AD. NPR levels in cortical homogenate were similar in wild-type (Wt) and APP/PS1 rats at 3 months of age (prior to Aβ plaque deposition), but significantly increased in APP/PS1 rats by 9 and 18-20 months of age (after the onset of plaque deposition). These agedependent differences were driven by proportional increases in NPR in membrane-associated cortical fractions. Genotype-related differences in NPR expression were also seen in the hippocampus, which exhibits significant Aβ pathology, but not in the cerebellum, which does not. Plasma analyses revealed increased levels of a 26 kDa NPR fragment in APP/PS1 rats relative to Wt rats by 18-20 months of age, which correlated with the levels of full-length NPR in cortex. Our findings indicate that cerebral accumulation of NPR and Aβ occurs with similar temporal and regional patterns in the APP/PS1 model, and suggest that a 26 kDa plasma NPR fragment may represent a peripheral biomarker of this process.
Introduction
Neuronal pentraxin receptor (NPR) is a membrane-associated protein that is almost exclusively produced in the brain (Dodds et al., 1997) . NPR is primarily found in excitatory synapses (Cho et al., 2008) , and exhibits particularly high levels of expression in the cerebral cortex, hippocampus, and cerebellum (Dodds et al., 1997) . It has been implicated in the regulation of glutamate neurotransmission in excitatory neurons. For example, in synapses, NPR binds to other members of the neuronal pentraxin protein family, including neuronal pentraxin 1 (NP1) and neuronal pentraxin 2 (NP2) (Kirkpatrick et al., 2000) , in order to recruit and cluster AMPA-type glutamate receptors (Xu et al., 2003; Sia et al., 2007; Koch and Ullian, 2010) . Furthermore, a key mechanistic step in the down-regulation of AMPA receptor neurotransmission required for long-term depression (LTD) is the cleavage of NPR by tumor necrosis factor-α converting enzyme (TACE) (Cho et al., 2008) . NPR may also mediate the uptake and clearance of synaptic debris in the process of synaptic remodeling (Bjartmar et al., 2006; Dodds et al., 1997; Kirkpatrick et al., 2000) .
The prominent role of NPR in synaptic plasticity raises the possibility that its expression may be altered in neurodegenerative conditions, such as Alzheimer's disease (AD), that are characterized by synaptic dysfunction and loss (Selkoe, 2002) . In particular, given the widespread disruption of glutamate neurotransmission seen with AD neuropathology (Revett et al., 2013) , NPR levels in cerebrospinal fluid (CSF) or peripheral blood may represent accessible markers of underlying dysfunction at excitatory synapses. However, the relationship between AD pathology and CSF NPR levels remains uncertain. Proteomic studies of CSF indicate that NPR levels are altered in sporadic late-onset AD patients relative to controls with normal cognition or other neurological conditions, with one group reporting increased levels in AD (Yin et al., 2009 ) and others reporting decreased levels in AD (Abdi et al., 2006; Finehout et al., 2007; Hu et al., 2007) . These apparently conflicting data reflect the possibility that CSF NPR levels may be modulated by underlying disease severity. One recent study that compared CSF samples from small groups of individuals with normal cognition or mild cognitive impairment (MCI), which often represents incipient AD, found higher NPR levels in MCI, though this result did not reach statistical significance (Wildsmith et al., 2014) . However, in the same study, the investigators
